Lynx1 Capital Management LP

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
TScan Therapeutics, Inc. 13G/A Amendment 3 TCRX · 89854M101	TCRX	89854M101	13.1%	20,519,148	13G/A Amendment 3	8/14/2026 Event 6/30/2026
Lynx1 Capital Management LP			13.1%	20,519,148
Weston Nichols			13.1%	20,519,148
Stoke Therapeutics, Inc. 13G/A Amendment 5 STOK · 86150R107	STOK	86150R107	6.5%	4,038,404	13G/A Amendment 5	8/14/2026 Event 6/30/2026
Lynx1 Capital Management LP			6.5%	4,038,404
Weston Nichols			6.5%	4,038,404
C4 Therapeutics, Inc. 13G/A Amendment 4 CCCC · 12529R107	CCCC	12529R107	10.0%	15,423,691	13G/A Amendment 4	8/14/2026 Event 6/30/2026
Lynx1 Capital Management LP			10.0%	15,423,691
Weston Nichols			10.0%	15,423,691
iBio, Inc. 13G IBIO · 451033708	IBIO	451033708	5.4%	2,807,016	13G	8/14/2026 Event 6/30/2026
Lynx1 Capital Management LP			5.4%	2,807,016
Weston Nichols			5.4%	2,807,016
GH Research PLC 13G/A Amendment 8 GHRS · G3855L106	GHRS	G3855L106	19.3%	13,263,288	13G/A Amendment 8	8/14/2026 Event 6/30/2026
Lynx1 Capital Management LP			19.3%	13,263,288
Weston Nichols			19.3%	13,263,288
Precision Biosciences Inc 13G DTIL · 74019P207	DTIL	74019P207	5.4%	1,390,611	13G	7/20/2026 Event 7/13/2026
Lynx1 Capital Management LP			5.4%	1,390,611
Weston Nichols			5.4%	1,390,611
Passage BIO, Inc. 13D PASG · 702712100	PASG	702712100	21.0%	673,759	13D	7/2/2026 Event 6/25/2026
Lynx1 Capital Management LP			21.0%	673,759
Weston Nichols			21.0%	673,759
GH Research PLC 13G/A Amendment 7 GHRS · G3855L106	GHRS	G3855L106	17.4%	10,763,288	13G/A Amendment 7	5/18/2026 Event 3/31/2026
Lynx1 Capital Management LP			17.4%	10,763,288
Weston Nichols			17.4%	10,763,288
Stoke Therapeutics, Inc. 13G/A Amendment 4 STOK · 86150R107	STOK	86150R107	8.1%	4,763,673	13G/A Amendment 4	5/18/2026 Event 3/31/2026
Lynx1 Capital Management LP			8.1%	4,763,673
Weston Nichols			8.1%	4,763,673
Allogene Therapeutics, Inc. 13G/A Amendment 1 ALLO · 019770106	ALLO	019770106	0%	0	13G/A Amendment 1	5/15/2026 Event 12/31/2025
Lynx1 Capital Management LP			0%	0
Weston Nichols			0%	0
GH Research PLC 13G/A Amendment 6 GHRS · G3855L106	GHRS	G3855L106	15.2%	9,456,622	13G/A Amendment 6	5/15/2026 Event 3/31/2026
Lynx1 Capital Management LP			15.2%	9,456,622
Weston Nichols			15.2%	9,456,622
Stoke Therapeutics, Inc. 13G/A Amendment 3 STOK · 86150R107	STOK	86150R107	7.0%	4,121,244	13G/A Amendment 3	5/15/2026 Event 3/31/2026
Lynx1 Capital Management LP			7.0%	4,121,244
Weston Nichols			7.0%	4,121,244
Agios Pharmaceuticals, Inc. 13G AGIO · 00847X104	AGIO	00847X104	5.1%	3,013,949	13G	5/6/2026 Event 4/29/2026
Lynx1 Capital Management LP			5.1%	3,013,949
Weston Nichols			5.1%	3,013,949
Korro Bio, Inc. 13G/A Amendment 1 KRRO · 500946108	KRRO	500946108	10.7%	1,538,296	13G/A Amendment 1	4/2/2026 Event 3/31/2026
Lynx1 Capital Management LP			10.7%	1,538,296
Weston Nichols			10.7%	1,538,296
iBio, Inc. 13G/A Amendment 1 IBIO · 451033708	IBIO	451033708	0%	0	13G/A Amendment 1	2/17/2026 Event 12/31/2025
Lynx1 Capital Management LP			0%	0
Weston Nichols			0%	0
Precision Biosciences Inc 13G/A Amendment 2 DTIL · 74019P207	DTIL	74019P207	4.1%	993,913	13G/A Amendment 2	2/17/2026 Event 12/31/2025
Lynx1 Capital Management LP			4.1%	993,913
Weston Nichols			4.1%	993,913
GH Research PLC 13G/A Amendment 5 GHRS · G3855L106	GHRS	G3855L106	16.8%	10,406,575	13G/A Amendment 5	2/17/2026 Event 12/31/2025
Lynx1 Capital Management LP			16.8%	10,406,575
Weston Nichols			16.8%	10,406,575
C4 Therapeutics, Inc. 13G/A Amendment 3 CCCC · 12529R107	CCCC	12529R107	7.3%	7,098,133	13G/A Amendment 3	2/17/2026 Event 12/31/2025
Lynx1 Capital Management LP			7.3%	7,098,133
Weston Nichols			7.3%	7,098,133
Korro Bio, Inc. 13G KRRO · 500946108	KRRO	500946108	7.8%	733,633	13G	1/5/2026 Event 12/23/2025
Lynx1 Capital Management LP			7.8%	733,633
Weston Nichols			7.8%	733,633
Neuphoria Therapeutics Inc. 13D/A Amendment 5 NEUP · 64136E102	NEUP	64136E102	16.3%	875,328	13D/A Amendment 5	12/29/2025 Event 12/26/2025
Lynx1 Capital Management LP			16.3%	875,328
Weston Nichols			16.3%	875,328
Neuphoria Therapeutics Inc. 13D/A Amendment 4 NEUP · 64136E102	NEUP	64136E102	16.3%	875,328	13D/A Amendment 4	12/2/2025 Event 12/2/2025
Lynx1 Capital Management LP			16.3%	875,328
Weston Nichols			16.3%	875,328
Neuphoria Therapeutics Inc. 13D/A Amendment 3 NEUP · 64136E102	NEUP	64136E102	16.3%	875,328	13D/A Amendment 3	11/28/2025 Event 11/28/2025
Lynx1 Capital Management LP			16.3%	875,328
Weston Nichols			16.3%	875,328
Neuphoria Therapeutics Inc. 13D/A Amendment 2 NEUP · 64136E102	NEUP	64136E102	16.3%	875,328	13D/A Amendment 2	11/18/2025 Event 11/18/2025
Lynx1 Capital Management LP			16.3%	875,328
Weston Nichols			16.3%	875,328
Precision Biosciences Inc 13G/A Amendment 1 DTIL · 74019P207	DTIL	74019P207	8.8%	1,042,596	13G/A Amendment 1	11/14/2025 Event 9/30/2025
LYNX1 Capital Management LP			8.8%	1,042,596
Weston Nichols			8.8%	1,042,596
Passage BIO, Inc. 13G/A Amendment 3 PASG · 702712100	PASG	702712100	19.6%	623,704	13G/A Amendment 3	11/14/2025 Event 9/30/2025
LYNX1 Capital Management LP			19.6%	623,704
Weston Nichols			19.6%	623,704
GH Research PLC 13G/A Amendment 4 GHRS · G3855L106	GHRS	G3855L106	13.9%	8,601,189	13G/A Amendment 4	11/14/2025 Event 9/30/2025
LYNX1 Capital Management LP			13.9%	8,601,189
Weston Nichols			13.9%	8,601,189
Cullinan Therapeutics, Inc. 13G/A Amendment 2 CGEM · 230031106	CGEM	230031106	9.8%	5,766,090	13G/A Amendment 2	11/14/2025 Event 9/30/2025
LYNX1 Capital Management LP			9.8%	5,766,090
Weston Nichols			9.8%	5,766,090
Neuphoria Therapeutics Inc. 13D/A Amendment 1 NEUP · 64136E102	NEUP	64136E102	26.5%	875,328	13D/A Amendment 1	11/10/2025 Event 11/9/2025
Lynx1 Capital Management LP			26.5%	875,328
Weston Nichols			26.5%	875,328
Neuphoria Therapeutics Inc. 13D NEUP · 64136E102	NEUP	64136E102	37.1%	875,328	13D	10/23/2025 Event 10/21/2025
Lynx1 Capital Management LP			37.1%	875,328
Weston Nichols			37.1%	875,328
Cullinan Therapeutics, Inc. 13G/A Amendment 1 CGEM · 230031106	CGEM	230031106	14.5%	8,549,084	13G/A Amendment 1	10/10/2025 Event 10/8/2025
Lynx1 Capital Management LP			14.5%	8,549,084
Weston Nichols			14.5%	8,549,084
TScan Therapeutics, Inc. 13G/A Amendment 2 TCRX · 89854M101	TCRX	89854M101	15.0%	7,857,347	13G/A Amendment 2	8/14/2025 Event 6/30/2025
Lynx1 Capital Management LP			15.0%	7,857,347
Weston Nichols			15.0%	7,857,347
Cullinan Therapeutics, Inc. 13G CGEM · 230031106	CGEM	230031106	7.5%	4,400,842	13G	8/14/2025 Event 6/30/2025
Lynx1 Capital Management LP			7.5%	4,400,842
Weston Nichols			7.5%	4,400,842
Allogene Therapeutics, Inc. 13G ALLO · 019770106	ALLO	019770106	5.2%	10,874,723	13G	2/14/2025 Event 12/31/2024
Lynx1 Capital Management LP			5.2%	10,874,723
Weston Nichols			5.2%	10,874,723
Passage BIO, Inc. 13G/A Amendment 2 PASG · 702712100	PASG	702712100	15.0%	9,256,953	13G/A Amendment 2	2/14/2025 Event 12/31/2024
Lynx1 Capital Management LP			15.0%	9,256,953
Weston Nichols			15.0%	9,256,953
Precision Biosciences Inc 13G DTIL · 74019P207	DTIL	74019P207	10.0%	766,051	13G	2/14/2025 Event 12/31/2024
Lynx1 Capital Management LP			10.0%	766,051
Weston Nichols			10.0%	766,051
TScan Therapeutics, Inc. 13G/A Amendment 1 TCRX · 89854M101	TCRX	89854M101	10.9%	5,357,347	13G/A Amendment 1	2/14/2025 Event 12/31/2024
Lynx1 Capital Management LP			10.9%	5,357,347
Weston Nichols			10.9%	5,357,347
GH Research PLC 13G/A Amendment 3 GHRS · G3855L106	GHRS	G3855L106	10.2%	6,353,069	13G/A Amendment 3	2/10/2025 Event 2/6/2025
Lynx1 Capital Management LP			10.2%	6,353,069
Weston Nichols			10.2%	6,353,069
GH Research PLC 13G/A Amendment 2 GHRS · G3855L106	GHRS	G3855L106	9.3%	4,858,994	13G/A Amendment 2	2/10/2025 Event 12/31/2024
Lynx1 Capital Management LP			9.3%	4,858,994
Weston Nichols			9.3%	4,858,994